Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Anti-leukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4+ infant ALL.

Bardini M, Trentin L, Rizzo F, Vieri M, Savino AM, Garrido Castro P, Fazio G, Van Roon EHJ, Kerstjens M, Smithers NN, Prinjha RK, Te Kronnie G, Basso G, Stam RW, Pieters R, Biondi A, Cazzaniga G.

Mol Cancer Ther. 2018 May 10. pii: molcanther.1123.2017. doi: 10.1158/1535-7163.MCT-17-1123. [Epub ahead of print]

PMID:
29748211
2.

Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo.

Kerstjens M, Pinhancos SS, Castro PG, Schneider P, Wander P, Pieters R, Stam RW.

Haematologica. 2018 Apr;103(4):e147-e150. doi: 10.3324/haematol.2017.174060. Epub 2018 Feb 1. No abstract available.

3.

NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.

Prieto C, López-Millán B, Roca-Ho H, Stam RW, Romero-Moya D, Rodríguez-Baena FJ, Sanjuan-Pla A, Ayllón V, Ramírez M, Bardini M, De Lorenzo P, Valsecchi MG, Stanulla M, Iglesias M, Ballerini P, Carcaboso ÁM, Mora J, Locatelli F, Bertaina A, Padilla L, Carlos Rodríguez-Manzaneque J, Bueno C, Menéndez P.

Leukemia. 2018 Mar;32(3):633-644. doi: 10.1038/leu.2017.294. Epub 2017 Sep 25.

4.

The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.

Garrido Castro P, van Roon EHJ, Pinhanços SS, Trentin L, Schneider P, Kerstjens M, Te Kronnie G, Heidenreich O, Pieters R, Stam RW.

Leukemia. 2018 Feb;32(2):323-331. doi: 10.1038/leu.2017.216. Epub 2017 Jul 10.

PMID:
28690313
5.

Updates in the biology and therapy for infant acute lymphoblastic leukemia.

Guest EM, Stam RW.

Curr Opin Pediatr. 2017 Feb;29(1):20-26. doi: 10.1097/MOP.0000000000000437. Review.

PMID:
27841777
6.

Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.

Mousavian Z, Nowzari-Dalini A, Stam RW, Rahmatallah Y, Masoudi-Nejad A.

Cell Oncol (Dordr). 2017 Feb;40(1):33-45. doi: 10.1007/s13402-016-0303-7. Epub 2016 Oct 31.

PMID:
27798768
7.

Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency.

Muñoz-López A, Romero-Moya D, Prieto C, Ramos-Mejía V, Agraz-Doblas A, Varela I, Buschbeck M, Palau A, Carvajal-Vergara X, Giorgetti A, Ford A, Lako M, Granada I, Ruiz-Xivillé N, Rodríguez-Perales S, Torres-Ruíz R, Stam RW, Fuster JL, Fraga MF, Nakanishi M, Cazzaniga G, Bardini M, Cobo I, Bayon GF, Fernandez AF, Bueno C, Menendez P.

Stem Cell Reports. 2016 Oct 11;7(4):602-618. doi: 10.1016/j.stemcr.2016.08.013. Epub 2016 Sep 22.

8.

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.

Kerstjens M, Driessen EM, Willekes M, Pinhanços SS, Schneider P, Pieters R, Stam RW.

Oncotarget. 2017 Feb 28;8(9):14835-14846. doi: 10.18632/oncotarget.11730.

9.

Versican expression is an adverse prognostic factor in MLL-rearranged infant acute lymphoblastic leukaemia.

Driessen EM, Pinhanços SS, Schneider P, de Lorenzo P, Valsecchi MG, Pieters R, Stam RW.

Eur J Cancer. 2016 Apr;57:87-90. doi: 10.1016/j.ejca.2015.12.031. Epub 2016 Feb 19. No abstract available.

PMID:
26901613
10.

Cellular Ontogeny and Hierarchy Influence the Reprogramming Efficiency of Human B Cells into Induced Pluripotent Stem Cells.

Muñoz-López Á, van Roon EH, Romero-Moya D, López-Millan B, Stam RW, Colomer D, Nakanishi M, Bueno C, Menendez P.

Stem Cells. 2016 Mar;34(3):581-7. doi: 10.1002/stem.2303. Epub 2016 Feb 25.

11.

Activated KRAS Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia.

Prieto C, Stam RW, Agraz-Doblas A, Ballerini P, Camos M, Castaño J, Marschalek R, Bursen A, Varela I, Bueno C, Menendez P.

Cancer Res. 2016 Apr 15;76(8):2478-89. doi: 10.1158/0008-5472.CAN-15-2769. Epub 2016 Feb 2.

12.

Immunophenotypic analysis and quantification of B-1 and B-2 B cells during human fetal hematopoietic development.

Bueno C, van Roon EH, Muñoz-López A, Sanjuan-Pla A, Juan M, Navarro A, Stam RW, Menendez P.

Leukemia. 2016 Jul;30(7):1603-6. doi: 10.1038/leu.2015.362. Epub 2015 Dec 29. No abstract available.

PMID:
26710885
13.

Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities.

van der Linden MH, Boer JM, Schneider P, Willekes M, Seslija L, De Lorenzo P, Valsecchi MG, Cazzaniga G, Biondi A, den Boer ML, Pieters R, Stam RW.

Haematologica. 2016 Mar;101(3):e95-8. doi: 10.3324/haematol.2014.122119. Epub 2015 Dec 17. No abstract available.

14.

Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.

Sanjuan-Pla A, Bueno C, Prieto C, Acha P, Stam RW, Marschalek R, Menéndez P.

Blood. 2015 Dec 17;126(25):2676-85. doi: 10.1182/blood-2015-09-667378. Epub 2015 Oct 13. Review.

15.

The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.

Stumpel DJ, Schneider P, Pieters R, Stam RW.

Eur J Cancer. 2015 Sep;51(14):2008-21. doi: 10.1016/j.ejca.2015.06.117. Epub 2015 Jul 15.

16.

Identification of genes transcriptionally responsive to the loss of MLL fusions in MLL-rearranged acute lymphoblastic leukemia.

van der Linden MH, Seslija L, Schneider P, Driessen EM, Castro PG, Stumpel DJ, van Roon E, de Boer J, Williams O, Pieters R, Stam RW.

PLoS One. 2015 Mar 20;10(3):e0120326. doi: 10.1371/journal.pone.0120326. eCollection 2015.

17.

MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.

van der Linden MH, Willekes M, van Roon E, Seslija L, Schneider P, Pieters R, Stam RW.

Cell Cycle. 2014;13(5):834-44. doi: 10.4161/cc.27757.

18.

Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.

Spijkers-Hagelstein JA, Schneider P, Pinhanços SM, Garrido Castro P, Pieters R, Stam RW.

Eur J Cancer. 2014 Jun;50(9):1665-74. doi: 10.1016/j.ejca.2014.03.011. Epub 2014 Apr 3.

PMID:
24703900
19.

Unique BHLHB3 overexpression in pediatric acute myeloid leukemia with t(6;11)(q27;q23).

Coenen EA, Zwaan CM, Stary J, Baruchel A, de Haas V, Stam RW, Reinhardt D, Kaspers GJ, Arentsen-Peters ST, Meyer C, Marschalek R, Nigro LL, Dworzak M, Pieters R, van den Heuvel-Eibrink MM.

Leukemia. 2014 Jul;28(7):1564-8. doi: 10.1038/leu.2014.82. Epub 2014 Feb 24. No abstract available.

PMID:
24561520
20.

Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.

Spijkers-Hagelstein JA, Pinhanços SS, Schneider P, Pieters R, Stam RW.

Leukemia. 2014 Apr;28(4):761-9. doi: 10.1038/leu.2013.245. Epub 2013 Aug 20.

PMID:
23958920
21.

The ongoing conundrum of MLL-AF4 driven leukemogenesis.

Stam RW.

Blood. 2013 May 9;121(19):3780-1. doi: 10.1182/blood-2013-03-491738. No abstract available.

22.

Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.

Driessen EM, van Roon EH, Spijkers-Hagelstein JA, Schneider P, de Lorenzo P, Valsecchi MG, Pieters R, Stam RW.

Haematologica. 2013 Jun;98(6):937-44. doi: 10.3324/haematol.2012.067983. Epub 2013 Feb 12.

23.

Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.

Spijkers-Hagelstein JA, Mimoso Pinhanços S, Schneider P, Pieters R, Stam RW.

Leukemia. 2013 Apr;27(5):1063-71. doi: 10.1038/leu.2012.372. Epub 2012 Dec 28.

PMID:
23334362
24.

CBL mutations do not frequently occur in paediatric acute myeloid leukaemia.

Coenen EA, Driessen EM, Zwaan CM, Stary J, Baruchel A, de Haas V, de Bont ES, Reinhardt D, Kaspers GJ, Arentsen-Peters ST, Meyer C, Marschalek R, Pieters R, Stam RW, van den Heuvel-Eibrink MM.

Br J Haematol. 2012 Dec;159(5):577-84. doi: 10.1111/bjh.12068. Epub 2012 Oct 1.

PMID:
23025505
25.

Absence of global hypomethylation in promoter hypermethylated Mixed Lineage Leukaemia-rearranged infant acute lymphoblastic leukaemia.

Stumpel DJ, Schneider P, van Roon EH, Pieters R, Stam RW.

Eur J Cancer. 2013 Jan;49(1):175-84. doi: 10.1016/j.ejca.2012.07.013. Epub 2012 Aug 23.

PMID:
22921182
26.

MLL-AF4 driven leukemogenesis: what are we missing?

Stam RW.

Cell Res. 2012 Jun;22(6):948-9. doi: 10.1038/cr.2012.16. Epub 2012 Jan 31. No abstract available.

27.

Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.

Kandimalla R, van Tilborg AA, Kompier LC, Stumpel DJ, Stam RW, Bangma CH, Zwarthoff EC.

Eur Urol. 2012 Jun;61(6):1245-56. doi: 10.1016/j.eururo.2012.01.011. Epub 2012 Jan 18.

PMID:
22284968
28.

Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.

Spijkers-Hagelstein JA, Schneider P, Hulleman E, de Boer J, Williams O, Pieters R, Stam RW.

Leukemia. 2012 Jun;26(6):1255-65. doi: 10.1038/leu.2011.388. Epub 2012 Jan 27.

PMID:
22282267
29.

Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.

Kang H, Wilson CS, Harvey RC, Chen IM, Murphy MH, Atlas SR, Bedrick EJ, Devidas M, Carroll AJ, Robinson BW, Stam RW, Valsecchi MG, Pieters R, Heerema NA, Hilden JM, Felix CA, Reaman GH, Camitta B, Winick N, Carroll WL, Dreyer ZE, Hunger SP, Willman CL.

Blood. 2012 Feb 23;119(8):1872-81. doi: 10.1182/blood-2011-10-382861. Epub 2011 Dec 30.

30.

Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia.

Stumpel DJ, Schneider P, Seslija L, Osaki H, Williams O, Pieters R, Stam RW.

Leukemia. 2012 Apr;26(4):682-92. doi: 10.1038/leu.2011.278. Epub 2011 Oct 21.

PMID:
22015773
31.

Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale.

Stumpel DJ, Schotte D, Lange-Turenhout EA, Schneider P, Seslija L, de Menezes RX, Marquez VE, Pieters R, den Boer ML, Stam RW.

Leukemia. 2011 Mar;25(3):429-39. doi: 10.1038/leu.2010.282. Epub 2010 Nov 30.

PMID:
21116279
32.

Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.

Schotte D, Lange-Turenhout EA, Stumpel DJ, Stam RW, Buijs-Gladdines JG, Meijerink JP, Pieters R, Den Boer ML.

Haematologica. 2010 Oct;95(10):1675-82. doi: 10.3324/haematol.2010.023481. Epub 2010 May 21.

33.

Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants.

Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, de Menezes RX, de Lorenzo P, Valsecchi MG, Pieters R.

Blood. 2010 Apr 8;115(14):2835-44. doi: 10.1182/blood-2009-07-233049. Epub 2009 Dec 23.

34.

Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.

Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG, de Lorenzo P, Sallan SE, Brady HJ, Armstrong SA, Pieters R.

Blood. 2010 Feb 4;115(5):1018-25. doi: 10.1182/blood-2009-02-205963. Epub 2009 Dec 4.

35.

Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.

Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG, de Menezes RX, Pieters R, Stam RW.

Blood. 2009 Dec 24;114(27):5490-8. doi: 10.1182/blood-2009-06-227660. Epub 2009 Oct 23.

36.

In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties.

le Viseur C, Hotfilder M, Bomken S, Wilson K, Röttgers S, Schrauder A, Rosemann A, Irving J, Stam RW, Shultz LD, Harbott J, Jürgens H, Schrappe M, Pieters R, Vormoor J.

Cancer Cell. 2008 Jul 8;14(1):47-58. doi: 10.1016/j.ccr.2008.05.015.

37.

Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia.

de Vries AC, Stam RW, Kratz CP, Zenker M, Niemeyer CM, van den Heuvel-Eibrink MM; European Working Group on childhood MDS (EWOG-MDS).

Haematologica. 2007 Nov;92(11):1574-5.

38.

D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia.

Stam RW, den Boer ML, Schneider P, Meier M, Beverloo HB, Pieters R.

Haematologica. 2007 Nov;92(11):1565-8.

39.

Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia.

de Vries AC, Stam RW, Schneider P, Niemeyer CM, van Wering ER, Haas OA, Kratz CP, den Boer ML, Pieters R, van den Heuvel-Eibrink MM.

Haematologica. 2007 Nov;92(11):1557-60.

40.

Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia.

Stam RW, Schneider P, de Lorenzo P, Valsecchi MG, den Boer ML, Pieters R.

Blood. 2007 Oct 1;110(7):2774-5. No abstract available.

41.

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.

Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R, Golub TR, Armstrong SA.

Cancer Cell. 2006 Oct;10(4):331-42. Epub 2006 Sep 28.

42.

Towards targeted therapy for infant acute lymphoblastic leukaemia.

Stam RW, den Boer ML, Pieters R.

Br J Haematol. 2006 Mar;132(5):539-51. Review.

PMID:
16445826
43.

Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.

Stam RW, den Boer ML, Passier MM, Janka-Schaub GE, Sallan SE, Armstrong SA, Pieters R.

Leukemia. 2006 Feb;20(2):264-71.

PMID:
16357833
44.

The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.

Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJ.

Br J Cancer. 2005 Dec 12;93(12):1388-94.

45.

Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias.

Van Vlierberghe P, Meijerink JP, Stam RW, van der Smissen W, van Wering ER, Beverloo HB, Pieters R.

Blood. 2005 Dec 15;106(13):4414-5. No abstract available.

46.

MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia.

Stam RW, Hubeek I, den Boer ML, Buijs-Gladdines JG, Creutzig U, Kaspers GJ, Pieters R.

Leukemia. 2006 Jan;20(1):179-82. No abstract available.

PMID:
16307022
47.

Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.

Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, van der Voort E, Valsecchi MG, de Lorenzo P, Sallan SE, Armstrong SA, Pieters R.

Blood. 2005 Oct 1;106(7):2484-90. Epub 2005 Jun 14.

48.

Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.

Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD, Pieters R.

Leukemia. 2004 Jan;18(1):78-83.

PMID:
14574327
49.

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, Pieters R, Kersey JH, Sallan SE, Fletcher JA, Golub TR, Griffin JD, Korsmeyer SJ.

Cancer Cell. 2003 Feb;3(2):173-83.

50.

Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.

Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, Janka-Schaub GE, Armstrong SA, Korsmeyer SJ, Pieters R.

Blood. 2003 Feb 15;101(4):1270-6. Epub 2002 Oct 24.

Supplemental Content

Support Center